CD8A and neoplasm: In tumor-bearing mouse studies, the activation of β-catenin in DCs resulted in more tolerogenic phenotypes than those mediated by the DC vaccine-induced cross-priming inhibition of anti-tumor CD8+ T cells by IL-10 (58).